Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Slides:

Advertisements

Similar presentations

Supplementary Figure S1.

Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Myeloid Suppressor Cells Accumulate and Regulate Blood Pressure in HypertensionNovelty and Significance by Kandarp H. Shah, Peng Shi, Jorge F. Giani, Tea.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Volume 18, Issue 2, Pages (August 2010)

by Norman Nausch, Ioanna E

Fig. 5 Maraba induces antitumor T cell immunity.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

CAR8 failure in an OT1 TCR transgenic T cell after exposure to OVA

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

by Adrienne Sallets, Sophie Robinson, Adel Kardosh, and Ronald Levy

Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 4 DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft tumor models. DMF enhances VSVΔ51 therapeutic efficacy in syngeneic and xenograft.

Volume 26, Issue 9, Pages (September 2018)

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated mice. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated.

Fig. 6. pKL cells revert hyperglycemia in NOD mice in vivo.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 4. Efficacy of C12G6 compared with and in combination with oseltamivir in mice. Efficacy of C12G6 compared with and in combination with oseltamivir.

Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects Jeffrey S. Moyer, Gabriel.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Fig. 5 Extended local release of R848 increases the number of innate and adaptive antitumor immune cells and cytokines. Extended local release of R848.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 6. Eradication of FLT3-ITD+ AML cells in vivo through combined inhibition of kinase and antiapoptotic pathways. Eradication of FLT3-ITD+ AML cells.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Fig. 8. Zbtb7a deficiency impairs antigen presentation by AMs.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 6 In utero injection of inflammatory cytokines or adoptive transfer of activated T cells leads to pregnancy loss. In utero injection of inflammatory.

IFN-γ–producing cells in the spleen and lungs postimmunization.

Antigen-specific immune responses are enhanced in hypertension.

APCs from hypertensive mice present antigens more efficiently.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

Treating ischemia via recruitment of antigen-specific T cells

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

Stereotactic radiotherapy increases Tregs in tumors.

5FU-induced specific activation of CD8+ T cells.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

CPI-444 enhances T-cell activation in MC38 tumors.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Ex vivo profiling of PD-1 blockade using MDOTS

Volume 25, Issue 4, Pages (April 2017)

Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.

Presentation transcript:

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. (A to C) μMt−mice were inoculated intramuscularly (i.m.) with 0.5 × 106 MC38 cells (day −8) and treated (n = 10 mice per group) with isotype control (133 μg, intravenously; day 2), radiation [3.6 Gray (Gy)/day; days 0 to 3], M7824 (55 μg, intravenously; day 2), or M7824 + radiation. (A) Tumor volumes, measured twice weekly. (B) Tumor weight (day 14). (C) ELISpot of IFN-γ–producing, p15E-responsive CD8+ T cells (day 14). Spleens were harvested (n = 5 mice), and CD8+ T cells were isolated. Antigen-presenting cells derived from naive splenocytes were pulsed with the KPSWFTTL (p15E) peptide or the irrelevant SIINFEKL (OVA) peptide, irradiated, and cultured with isolated CD8+ T cells. (D to F) C57BL/6 mice were inoculated intramuscularly (day −7) with 0.5 × 106 MC38 cells in the right thigh (primary tumor) and subcutaneously (s.c.) with 1 × 106 MC38 cells in the left flank (secondary tumor) and treated (n = 6 mice per group) with isotype control (400 μg; days 0, 2, and 4), radiation (5 Gy/day; days 0 to 3), M7824 (164 μg; day 0), or M7824 + radiation. Radiation was applied only to the primary tumor, as shown in (D). (E) Primary tumor volumes and (F) secondary tumor volumes were measured twice weekly. (G to I) μMt− mice were subcutaneously inoculated with 1 × 106 MC38 cells (day −7) and treated (n = 10 mice per group) with isotype control (400 μg; days 3, 6, 9, 12, and 17), M7824 (492 μg, intravenously; days 3, 6, 9, 12, and 17), oxaliplatin (Ox)/5-fluorouracil (5-FU) (5 mg/kg, intraperitoneally, and 60 mg/kg, intravenously; day 0), or M7824 + Ox/5-FU. (G) Tumor volumes were measured twice weekly. (H) Tumor weight (day 18). (I) ELISpot of IFN-γ–producing, p15E-responsive CD8+ T cells (n = 5 mice). Tumor volumes are presented as mean ± SEM. **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001 denote a significant difference relative to radiation + M7824 treatment or Ox/5-FU + M7824 treatment. Tumor weights are shown for individual mice, with lines representing the means, and they were compared by unpaired t test. IFN-γ ELISpot data are means ± SEM of three replicates and were evaluated by two-way ANOVA. Yan Lan et al., Sci Transl Med 2018;10:eaan5488 Published by AAAS